



DUPLOSPRAY MIS

Endoscopic Spray System

Easy. Safety Features. Complete Coverage.

Easy to Use


- Roll stand offers a mobile, self-contained system for easy transport and fast setup.
- Three convenient lengths.

Unique Safety Features

- Designed exclusively for use with CO₂ gas only – primary gas of choice to use in laparoscopic procedures.
- Patient vent line – dynamically vents gas through the trocar vent valve, providing pressure stability during application.
- Reduced gas flow rate – flow rate of DUPLOSPRAY MIS is approximately 2 L/min. Open gas spray systems (not designed for endoscopic use) can have flow rates as high as 20 L/min.^{2,3}
- Pressure gauge readings above 25 psi / 1.7 bar (red zone) will cause regulator's internal safety relief valve to release pressure safely inside regulator assembly with an audible signal.

High Performance*

- Thin, uniform spray enables consistent product utilization and broad area coverage.
 - Rigid stainless steel cannula.
- *As compared to a manual spray device.



Topical Use Only

For safe and proper use of this device please see full device Instructions for use.

*Regulator and roll stand provided at no charge with purchase of 2 cases of applicators, any length.



*TISSEEL [Fibrin Sealant] and DUPLOSPRAY MIS are sold separately
Products are not shown actual size.



DUPLOSPRAY MIS

Endoscopic Spray System

Order codes #	Description	Pack Factor
0600030	DUPLOSPRAY MIS Applicator 40cm, for use with TISSEEL [Fibrin Sealant]	5
0600029	DUPLOSPRAY MIS Applicator 30cm, for use with TISSEEL [Fibrin Sealant]	5
0600033	DUPLOSPRAY MIS Applicator 20cm, for use with TISSEEL [Fibrin Sealant]	5
0600031	Replacement Tips - DUPLOSPRAY MIS Applicator	10
0600032	DUPLOSPRAY MIS Regulator	1
0600040	DUPLOSPRAY MIS System Roll Stand	1

To order, call 1-800-423-2090
www.baxterbiosurgery.com

TISSEEL [Fibrin Sealant] Indications and Usage

TISSEEL is indicated for use as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of splenic injuries due to blunt or penetrating trauma to the abdomen, when control of bleeding by conventional surgical techniques, including suture, ligature and cautery, is ineffective or impractical. TISSEEL is a satisfactory hemostatic agent in fully heparinized patients undergoing cardiopulmonary bypass.

TISSEEL has been shown to be an effective sealant as an adjunct in the closure of colostomies.

Important Risk Information for TISSEEL

For Topical Use Only. Do not inject TISSEEL directly into the circulatory system. Intravascular application of TISSEEL may result in life-threatening thromboembolic events. Caution should be exercised to minimize any risk of inadvertent intravascular application.

Do not use TISSEEL in individuals with a known hypersensitivity to aprotinin.

Do not use TISSEEL for the treatment of severe or brisk arterial bleeding. In these situations, TISSEEL will be washed away in the flow of blood before hemostasis can be attained.

Hypersensitivity or allergic/anaphylactoid reactions may occur with the use of TISSEEL. Symptoms associated with allergic reactions include: flush, urticaria, pruritus, nausea, drop in blood pressure, tachycardia or bradycardia, dyspnea, severe hypotension and anaphylactic shock. Such reactions may also occur in patients receiving TISSEEL for the first time.

Discontinue administration of TISSEEL in the event of hypersensitivity reactions.

Apply as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.

Air or gas embolism has occurred with the use of spray devices employing a pressure regulator to administer fibrin sealants. This event appears to be related to use of the spray device at higher than recommended pressures and in close proximity to the tissue surface.

When applying fibrin sealants using a spray device, be sure to use the pressure within the pressure range recommended by the spray device manufacturer.

Exposure to solutions containing alcohol, iodine or heavy metals may cause TISSEEL to be denatured. If any of these substances have been used to clean the wound area, the area must be thoroughly rinsed before the application of TISSEEL.

The safety and effectiveness of TISSEEL used alone or in combination with biocompatible carriers in neurosurgical procedures or other surgeries involving confined spaces have not been evaluated; its use in this setting is not FDA approved.

There have been rare reports of serious adverse events such as paralysis and other compressive complications possibly related to the use of fibrin sealant in combination with resorbable hemostatic agents.

TISSEEL is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying full Prescribing Information.

Baxter Healthcare Corporation | One Baxter Parkway, Deerfield, IL 60015

Baxter, Tisseel and Duplospray are registered trademarks of Baxter International Inc.

References

1. S.J. Neuhaus, *Helium and other alternative insufflation gases for laparoscopy*.
2. DUPLOSPRAY MIS Instructions For Use; PN21281, Rev.A.
3. EasySpray Set Instructions For Use; 62084006H07.